NOTV
Inotiv, Inc.
NASDAQ · Healthcare · Medical - Diagnostics & Research · US
$0.08
+121.94%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 507.4M | 513.0M | 490.7M | 572.4M | 547.7M |
| Cost of Revenue | 432.8M | 448.0M | 379.6M | 407.0M | 390.4M |
| Gross Profit | 74.6M | 65.1M | 111.2M | 165.4M | 157.2M |
| Operating Expenses | |||||
| R&D Expense | — | — | — | — | — |
| SG&A Expense | 92.9M | 92.2M | 97.9M | 127.3M | 99.1M |
| General & Admin Expense | 70.9M | 71.1M | 77.0M | 108.2M | 82.4M |
| Selling & Marketing Expense | 22.0M | 21.1M | 20.9M | 19.1M | 16.6M |
| Other Expenses | 26.7M | 3.7M | 99.7M | 119.6M | 85.6M |
| Total Operating Expenses | 119.6M | 96.0M | 197.6M | 246.9M | 184.7M |
| Cost and Expenses | 552.4M | 543.9M | 577.1M | 653.9M | 575.1M |
| Operating Income (EBIT) | (45.0M) | (30.9M) | (86.4M) | (81.5M) | (27.4M) |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | 56.8M | 56.6M | 46.9M | 43.0M | 29.7M |
| Net Interest Income | (56.8M) | (56.6M) | (46.9M) | (43.0M) | (29.7M) |
| Other Non-Op Income/Expense | (60.7M) | (56.9M) | (44.4M) | (42.8M) | (89.0M) |
| Non-Operating Income (excl Interest) | 586.0K | 273.0K | (2.5M) | (237.0K) | 59.3M |
| EBT (Pre-Tax Income) | (105.7M) | (87.8M) | (130.8M) | (124.2M) | (352.4M) |
| Income Tax Expense | (18.8M) | (19.1M) | (21.9M) | (19.3M) | (15.2M) |
| Bottom Line | |||||
| Net Income | (87.0M) | (68.6M) | (108.4M) | (105.1M) | (337.3M) |
| Earnings from Cont. Ops | (87.0M) | (68.6M) | (108.9M) | (104.9M) | (337.3M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (87.0M) | (68.6M) | (108.4M) | (105.1M) | (337.0M) |
| Per Share | |||||
| Basic EPS | ($2.53) | ($2.11) | ($4.19) | ($4.10) | ($13.85) |
| Diluted EPS | ($2.53) | ($2.11) | ($4.19) | ($4.10) | ($13.85) |
| Revenue Per Share | $14.64 | $15.81 | $18.95 | $22.32 | $22.49 |
| Shares | |||||
| Basic Shares Outstanding | 34.7M | 32.5M | 25.9M | 25.6M | 24.4M |
| Diluted Shares Outstanding | 34.7M | 32.5M | 25.9M | 25.6M | 24.4M |
| Profitability Metrics | |||||
| EBITDA | 10.2M | 24.8M | (26.8M) | (26.5M) | (273.4M) |
| D&A | 55.8M | 55.9M | 57.1M | 54.7M | 49.3M |
| EBIT | (45.6M) | (31.2M) | (83.9M) | (81.2M) | (322.7M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026